0001415889-24-009450.txt : 20240329
0001415889-24-009450.hdr.sgml : 20240329
20240329175926
ACCESSION NUMBER: 0001415889-24-009450
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240327
FILED AS OF DATE: 20240329
DATE AS OF CHANGE: 20240329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hohl Benjamin
CENTRAL INDEX KEY: 0001882764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 24805029
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
4
1
form4-03292024_090320.xml
X0508
4
2024-03-27
0001672619
Enliven Therapeutics, Inc.
ELVN
0001882764
Hohl Benjamin
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
false
true
false
false
CHIEF FINANCIAL OFFICER
1
Common Stock
2024-03-27
4
M
0
3250
2.48
A
3250
D
Common Stock
2024-03-27
4
S
0
3068
18.2189
D
182
D
Common Stock
2024-03-27
4
S
0
182
18.7186
D
0
D
Stock Option (right to buy)
2.48
2024-03-27
4
M
0
3250
0
D
2031-08-02
Common Stock
3250
239370
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
This transaction was executed in multiple trades at prices ranging from $17.69 to $18.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $18.69 to $18.755. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
/s/ Benjamin Hohl
2024-03-29